Did Cancer Trial Wins Just Shift Merck (MRK) Stock Investment Narrative?
Did Cancer Trial Wins Just Shift Merck (MRK) Stock Investment Narrative? Simply Wall St
Covered in this story
Analyst targets on Merck & Co.
- Freedom Broker: $149 → $140 by Nov 2027 via Investing.com Canada
- Guggenheim: $150 → $171 by Oct 2027 · Buy via Investing.com
- RBC Capital Markets: $145 → $145 by Oct 2027 · Sector Perform via MarketBeat
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $MRK yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Merck & Co. →Dalsna Finance is currently tracking 38 stories mentioning Merck & Co., the earliest published 24 Jun 2026.
Summary aggregated from Simply Wall St's public RSS feed. The full reporting belongs to Simply Wall St — please read it on their site.